Angiotensin-converting enzyme - New insights into structure, biological significance and prospects for domain-selective inhibitors

Current Enzyme Inhibition

Volumn 5, Issue 3, 2009, Pages 134-147

  Watermeyer, Jean M ^a   Kröger, Wendy L ^a   Sturrock, Edward D ^a   Ehlers, Mario R W ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AcSDKP; Angiotensin converting enzyme (ACE); Crystal; Domain selective inhibitors; Metallopeptidase; Structure

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; NEUROLYSIN; RXP 407; RXPA 380; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CIRCULAR DICHROISM; CONFORMATION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME DENATURATION; ENZYME INACTIVATION; ENZYME STRUCTURE; GENE LOCUS; GENE MUTATION; HORMONE ACTION; HUMAN; HYDROLYSIS; KIDNEY DISEASE; NONHUMAN; PROTEIN DOMAIN; PROTEIN SYNTHESIS; REVIEW; SEQUENCE HOMOLOGY; STRUCTURAL HOMOLOGY; TANDEM REPEAT; TRANSGENE;

EID: 70350006638     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340809789071155     Document Type: Review

References (106)

1. Zaman, M.A.; Oparil, S.; Calhoun, D.A. Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov., 2002, 1, 621-636.
2. Turner, A.J.; Hooper, N.M. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends. Pharmacol. Sci., 2002, 23, 177-183.
3. Soubrier, F.; Alhenc-Gelas, F.; Hubert, C.; Allegrini, J.; John, M.; Tregear, G.; Corvol, P. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. USA, 1988, 85, 9386-9390.
4. Wei, L.; Alhenc-Gelas, F.; Corvol, P.; Clauser, E. The 2 homologous domains of human angiotensin-I-converting enzyme are both catalytically active. J. Biol. Chem., 1991, 266, 9002-9008.
5. Wei, L.; Clauser, E.; Alhenc-Gelas, F.; Corvol, P. The 2 homologous domains of human angiotensin-I-converting enzyme interact differently with competitive inhibitors. J. Biol. Chem., 1992, 267, 13398-13405.
6. Voronov, S.; Zueva, N.; Orlov, V.; Arutyunyan, A.; Kost, O. Temperature-induced selective death of the C-domain within angiotensin-converting enzyme molecule. FEBS Lett., 2002, 522, 77-82.
7. Hubert, C.; Houot, A.M.; Corvol, P.; Soubrier, F. Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J. Biol. Chem., 1991, 266, 15377-15383.
8. Ehlers, M.R.; Fox, E.A.; Strydom, D.J.; Riordan, J.F. Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc. Natl. Acad. Sci. USA, 1989, 86, 7741-7745.
9. Langford, K.G.; Zhou, Y.; Russell, L.D.; Wilcox, J.N.; Bernstein, K.E. Regulated expression of testis angiotensin-converting enzyme during spermatogenesis in mice. Biol. Reprod., 1993, 48, 1210-1218.
10. Esther, C.R.; Jr.; Semeniuk, D.; Marino, E.M.; Zhou, Y.; Overbeek, P.A.; Bernstein, K.E. Expression of testis angiotensin-converting enzyme is mediated by a cyclic AMP responsive element. Lab. Invest., 1997, 77, 483-488.
11. Turner, A.J.; Hiscox, J.A.; Hooper, N.M. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol. Sci., 2004, 25, 291-294.
12. Warner, F.J.; Smith, A.I.; Hooper, N.M.; Turner, A.J. Angiotensin-converting enzyme-2: a molecular and cellular perspective. Cell. Mol. Life Sci., 2004, 61, 2704-2713.
13. Acharya, K.R.; Sturrock, E.D.; Riordan, J.F.; Ehlers, M.R. ACE revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov., 2003, 2, 891-902.
14. Natesh, R.; Schwager, S.L.; Sturrock, E.D.; Acharya, K.R. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature, 2003, 421, 551-554.
15. Natesh, R.; Schwager, S.L.; Evans, H.R.; Sturrock, E.D.; Acharya, K.R. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry, 2004, 43, 8718-8724.
16. Sturrock, E.D.; Natesh, R.; van Rooyen, J.M.; Acharya, K.R. Structure of angiotensin I-converting enzyme. Cell. Mol. Life Sci., 2004, 61, 2677-2686.
17. Watermeyer, J.M.; Sewell, B.T.; Schwager, S.L.; Natesh, R.; Corradi, H.R.; Acharya, K.R.; Sturrock, E.D. Structure of testis ACE glycosylation mutants and evidence for conserved domain movement. Biochemistry, 2006, 45, 12654-12663.
18. Corradi, H.R.; Schwager, S.L.; Nchinda, A.T.; Sturrock, E.D.; Acharya, K.R. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J. Mol. Biol., 2006, 357, 964-974.
19. Corradi, H.R.; Chitapi, I.; Sewell, B.T.; Georgiadis, D.; Dive, V.; Sturrock, E.D.; Acharya, K.R. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry, 2007, 46, 5473-5478.
20. Bergdoll, M.; Eltis, L.D.; Cameron, A.D.; Dumas, P.; Bolin, J.T. All in the family: structural and evolutionary relationships among three modular proteins with diverse functions and variable assembly. Protein Sci., 1998, 7, 1661-1670.
21. Díaz-Mejía, J.J.; Pérez-Rueda, E.; Segovia, L. A network perspective on the evolution of metabolism by gene duplication. Genome Biol., 2007, 8, R26.
22. Hunziker, W.; Spiess, M.; Semenza, G.; Lodish, H.F. The sucrase-isomaltase complex: primary structure, membrane-orientation, and evolution of a stalked, intrinsic brush border protein. Cell, 1986, 46, 227-234.
23. Mantei, N.; Villa, M.; Enzler, T.; Wacker, H.; Boll, W.; James, P.; Hunziker, W.; Semenza, G. Complete primary structure of human and rabbit lactase-phlorizin hydrolase: implications for biosynthesis, membrane anchoring and evolution of the enzyme. EMBO J., 1988, 7, 2705-2713.
24. Song, L.; Fricker, L.D. Purification and characterization of carboxypeptidase D, a novel carboxypeptidase E-like enzyme, from bovine pituitary. J. Biol. Chem., 1995, 270, 25007-25013.
25. Song, L.; Fricker, L.D. Tissue distribution and characterization of soluble and membrane-bound forms of metallocarboxypeptidase D. J. Biol. Chem., 1996, 271, 28884-28889.
26. Tan, F.; Rehli, M.; Krause, S.W.; Skidgel, R.A. Sequence of human carboxypeptidase D reveals it to be a member of the regulatory carboxypeptidase family with three tandem active site domains. Biochem. J., 1997, 327 (Pt 1), 81-87.
27. Henrissat, B.; Bairoch, A. New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem. J., 1993, 293 (Pt 3), 781-788.
28. Saxena, I.M.; Brown, R.M.; Jr.; Fevre, M.; Geremia, R.A.; Henrissat, B. Multidomain architecture of beta-glycosyl transferases: implications for mechanism of action. J. Bacteriol., 1995, 177, 1419-1424.
29. Henrissat, B.; Callebaut, I.; Fabrega, S.; Lehn, P.; Mornon, J.P.; Davies, G. Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases. Proc. Natl. Acad. Sci. USA, 1995, 92, 7090-7094.
30. Henrissat, B. A classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem. J., 1991, 280 (Pt 2), 309-316.
31. Zecca, L.; Mesonero, J.E.; Stutz, A.; Poirée, J.C.; Giudicelli, J.; Cursio, R.; Gloor, S.M.; Semenza, G. Intestinal lactase-phlorizin hydrolase (LPH): the two catalytic sites; the role of the pancreas in pro-LPH maturation. FEBS Lett., 1998, 435, 225-228.
32. Arribas, J.C.; Herrero, A.G.; Martín-Lomas, M.; Cañada, F.J.; He, S.; Withers, S.G. Differential mechanism-based labeling and unequivocal activity assignment of the two active sites of intestinal lactase/phlorizin hydrolase. Eur. J. Biochem., 2000, 267, 6996-7005.
33. Schlegel-Haueter, S.; Hore, P.; Kerry, K.R.; Semenza, G. The preparation of lactase and glucoamylase of rat small intestine. Biochim. Biophys. Acta, 1972, 258, 506-519.
34. Kraml, J.; Kolínská, J.; Eddederová, D.; Hirsová, D. β-Glucosidase (phlorizin hydrolase) activity of the lactase fraction isolated from the small intestinal mucosa of infant rats, and the relationship between β-glucosidases and β-galactosidases. Biochim. Biophys. Acta, 1972, 258, 520-530.
35. Colombo, V.; Lorenz-Meyer, H.; Semenza, G. Small intestinal phlorizin hydrolase: the "beta-glycosidase complex". Biochim. Biophys. Acta, 1973, 327, 412-424.
36. Skovbjerg, H.; Sjöström, H.; Norén, O. Purification and characterisation of amphiphilic lactase/phlorizin hydrolase from human small intestine. Eur. J. Biochem., 1981, 114, 653-661.
37. Jacob, R.; Pürschel, B.; Naim, H.Y. Sucrase is an intramolecular chaperone located at the C-terminal end of the sucrase-isomaltase enzyme complex. J. Biol. Chem., 2002, 277, 32141-32148.
38. Georgiadis, D.; Beau, F.; Czarny, B.; Cotton, J.; Yiotakis, A.; Dive, V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin - Insights from selective inhibitors. Circ. Res., 2003, 93, 148-154.
39. Ehlers, M.R.; Riordan, J.F. Angiotensin-converting enzyme: zinc-and inhibitor-binding stoichiometries of the somatic and testis isozymes. Biochemistry, 1991, 30, 7118-7126.
40. Woodman, Z.L.; Schwager, S.L.; Redelinghuys, P.; Carmona, A.K.; Ehlers, M.R.; Sturrock, E.D. The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity. Biochem. J., 2005, 389, 739-744.
41. Balyasnikova, I.V.; Skirgello, O.E.; Binevski, P.V.; Nesterovitch, A.B.; Albrecht, R.F.; Kost, O.A.; Danilov, S.M. Monoclonal antibodies 1G12 and 6A12 to the N-domain of human angiotensin-converting enzyme: Fine epitope mapping and antibody-based detection of ACE inhibitors in human blood. J. Proteome Res., 2007, 6, 1580-1594.
42. Binevski, P.V.; Sizova, E.A.; Pozdnev, V.F.; Kost, O.A. Evidence for the negative cooperativity of the two active sites within bovine somatic angiotensin-converting enzyme. FEBS Lett., 2003, 550, 84-88.
43. Skirgello, O.; Kost, O.; Balyasnikova, I.; Sun, Z.L.; Albrecht, R.; Danilov, S. Anti-catalytic antibodies for angiotensin I-converting enzyme: inhibitory effect and fine epitope mapping. FEBS J., 2005, 272, 18-19.
44. Andújar-Sánchez, M.; Jara-Pérez, V.; Cámara-Artigas, A. Thermo-dynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett., 2007, 581, 3449-3454.
45. O'Neill, H.G.; Redelinghuys, P.; Schwager, S.L.; Sturrock, E.D. The role of glycosylation and domain interactions in the thermal stability of human angiotensin-converting enzyme. Biol. Chem., 2008, 389, 1153-1161.
46. Danilov, S.M.; Balyasnikova, I.V.; Albrecht, R.F.; Kost, O.A. Simultaneous determination of ACE activity with 2 substrates provides information on the status of somatic ACE and allows detection of inhibitors in human blood. J. Cardiovasc. Pharmacol., 2008, 52, 90-103.
47. Eng, F.J.; Novikova, E.G.; Kuroki, K.; Ganem, D.; Fricker, L.D. gp180, a protein that binds duck hepatitis B virus particles, has metallocarboxypeptidase D-like enzymatic activity. J. Biol. Chem., 1998, 273, 8382-8388.
48. Novikova, E.G.; Eng, F.J.; Yan, L.; Qian, Y.; Fricker, L.D. Characterization of the enzymatic properties of the first and second domains of metallocarboxypeptidase D. J. Biol. Chem., 1999, 274, 28887-28892.
49. Seidah, N.G.; Day, R.; Hamelin, J.; Gaspar, A.; Collard, M.W.; Chrétien, M. Testicular expression of PC4 in the rat: molecular diversity of a novel germ cell-specific Kex2/subtilisin-like proprotein convertase. Mol. Endocrinol., 1992, 6, 1559-1570.
50. Schafer, M.K.; Day, R.; Cullinan, W.E.; Chrétien, M.; Seidah, N.G.; Watson, S.J. Gene expression of prohormone and proprotein convertases in the rat CNS: a comparative in situ hybridization analysis. J. Neurosci., 1993, 13, 1258-1279.
51. Seidah, N.G.; Chrétien, M.; Day, R. The family of subtilisin/kexin like pro-protein and pro-hormone convertases: divergent or shared functions. Biochimie, 1994, 76, 197-209.
52. Zheng, M.; Streck, R.D.; Scott, R.E.; Seidah, N.G.; Pintar, J.E. The developmental expression in rat of proteases furin, PC1, PC2, and carboxypeptidase E: implications for early maturation of proteolytic processing capacity. J. Neurosci., 1994, 14, 4656-4673.
53. Seidah, N.G.; Hamelin, J.; Mamarbachi, M.; Dong, W.; Tardos, H.; Mbikay, M.; Chrétien, M.; Day, R. cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc. Natl. Acad. Sci. USA, 1996, 93, 3388-3393.
54. Johnson, R.G.; Scarpa, A. Internal pH of isolated chromaffin vesicles. J. Biol. Chem., 1976, 251, 2189-2191.
55. 2+ ATPase in neurosecretory vesicles isolated from bovine neurohypophyses. J. Biol. Chem., 1984, 259, 9496-9507.
56. Gomis-Rüth, F.X.; Companys, V.; Qian, Y.; Fricker, L.D.; Vendrell, J.; Avilés, F.X.; Coll, M. Crystal structure of avian carboxypeptidase D domain II: a prototype for the regulatory metallocarboxypeptidase subfamily. EMBO J., 1999, 18, 5817-5826.
57. Aloy, P.; Companys, V.; Vendrell, J.; Avilés, F.X.; Fricker, L.D.; Coll, M.; Gomis-Rüth, F.X. The crystal structure of the inhibitor-complexed carboxypeptidase D domain II and the modeling of regulatory carboxypeptidases. J. Biol. Chem., 2001, 276, 16177-16184.
58. Ehlers, M.R.; Riordan, J.F. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry, 1989, 28, 5311-5318.
59. Tipnis, S.R.; Hooper, N.M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A.J. A human homolog of angiotensin-converting enzyme - Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem., 2000, 275, 33238-33243.
60. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; Breitbart, R.E.; Acton, S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res., 2000, 87, E1-E9.
61. Turner, A.J.; Tipnis, S.R.; Guy, J.L.; Rice, G.I.; Hooper, N.M. ACEH/ ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can. J.Physiol. Pharmacol., 2002, 80, 346-353.
62. Towler, P.; Staker, B.; Prasad, S.G.; Menon, S.; Tang, J.; Parsons, T.; Ryan, D.; Fisher, M.; Williams, D.; Dales, N.A.; Patane, M.A.; Pantoliano, M.W. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem., 2004, 279, 17996-18007.
63. Guy, J.L.; Jackson, R.M.; Acharya, K.R.; Sturrock, E.D.; Hooper, N.M.; Turner, A.J. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry, 2003, 42, 13185-13192.
64. Williams, T.A.; Michaud, A.; Houard, X.; Chauvet, M.T.; Soubrier, F.; Corvol, P. Drosophila melanogaster angiotensin I-converting enzyme expressed in Pichia pastoris resembles the C domain of the mammalian homologue and does not require glycosylation for secretion and enzymic activity. Biochem. J., 1996, 318 (Pt 1), 125-131.
65. Bingham, R.J.; Dive, V.; Phillips, S.E.; Shirras, A.D.; Isaac, R.E. Structural diversity of angiotensin-converting enzyme. FEBS J. 2006, 273, 362-373.
66. Kim, H.M.; Shin, D.R.; Yoo, O.J.; Lee, H.; Lee, J.O. Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. FEBS Lett., 2003, 538, 65-70.
67. Hooper, N.M. Families of zinc metalloproteases. FEBS Lett., 1994, 354, 1-6.
68. Rawlings, N.D.; Barrett, A.J. Evolutionary families of metallopeptidases. Methods Enzymol., 1995, 248, 183-228.
69. Spyroulias, G.A.; Galanis, A.S.; Pairas, G.; Manessi-Zoupa, E.; Cordopatis, P. Structural features of angiotensin-I converting enzyme catalytic sites: conformational studies in solution, homology models and comparison with other zinc metallopeptidases. Curr. Top. Med. Chem., 2004, 4, 403-429.
70. Ray, K.; Hines, C.S.; Coll-Rodríguez, J.; Rodgers, D.W. Crystal structure of human thimet oligopeptidase provides insight into substrate recognition, regulation, and localization. J. Biol. Chem., 2004, 279, 20480-20489.
71. Brown, C.K.; Madauss, K.; Lian, W.; Beck, M.R.; Tolbert, W.D.; Rodgers, D.W. Structure of neurolysin reveals a deep channel that limits substrate access. Proc. Natl. Acad. Sci. USA, 2001, 98, 3127-3132.
72. Lim, E.J.; Sampath, S.; Coll-Rodríguez, J.; Schmidt, J.; Ray, K.; Rodgers, D.W. Swapping the substrate specificities of the neuropeptidases neurolysin and thimet oligopeptidase. J. Biol. Chem., 2007, 282, 9722-9732.
73. Comellas-Bigler, M.; Lang, R.; Bode, W.; Maskos, K. Crystal structure of the E. coli dipeptidyl carboxypeptidase Dcp: further indication of a ligand-dependent hinge movement mechanism. J. Mol. Biol., 2005, 349, 99-112.
74. Nagata, K.; Tsutsui, S.; Lee, W.C.; Ito, K.; Kamo, M.; Inoue, Y.; Tanokura, M. Crystallization and preliminary X-ray analysis of carboxypeptidase 1 from Thermus thermophilus. Acta Crystallogr.; Sect. D: Biol. Crystallogr., 2004, 60, 1445-1446.
75. Gerdts, C.J.; Tereshko, V.; Yadav, M.K.; Dementieva, I.; Collart, F.; Joachimiak, A.; Stevens, R.C.; Kuhn, P.; Kossiakoff, A.; Ismagilov, R.F. Time-controlled microfluidic seeding in nL-volume droplets to separate nucleation and growth stages of protein crystallization. Angew. Chem. Int. Ed., 2006, 45, 8156-8160.
76. Niemirowicz, G.; Fernández, D.; Solà, M.; Cazzulo, J.J.; Avilés, F.X.; Gomis-Rüth, F.X. The molecular analysis of Trypanosoma cruzi metallocarboxypeptidase 1 provides insight into fold and substrate specificity. Mol. Microbiol., 2008, 70, 853-866.
77. Arndt, J.W.; Hao, B.; Ramakrishnan, V.; Cheng, T.; Chan, S.I.; Chan, M.K. Crystal structure of a novel carboxypeptidase from the hyperthermophilic archaeon Pyrococcus furiosus. Structure, 2002, 10, 215-224.
78. Tyndall, J.D.; Nall, T.; Fairlie, D.P. Proteases universally recognize beta strands in their active sites. Chem. Rev., 2005, 105, 973-999.
79. Watermeyer, J.M.; Sewell, B.T.; Schwager, S.L.; Natesh, R.; Corradi, H.R.; Acharya, K.R.; Sturrock, E.D. Structure of testis ACE glycosylation mutants and evidence for conserved domain movement. Biochemistry, 2006, 45, 12654-12663.
80. Skirgello, O.E.; Balyasnikova, I.V.; Binevski, P.V.; Sun, Z.L.; Baskin, I.I.; Palyulin, V.A.; Nesterovitch, A.B.; Albrecht, R.F.; Kost, O.A.; Danilov, S.M. Inhibitory antibodies to human angiotensin-converting enzyme: fine epitope mapping and mechanism of action. Biochemistry, 2006, 45, 4831-4847.
81. Andújar-Sánchez, M.; Cámara-Artigas, A.; Jara-Pérez, V. A calorimetric study of the binding of lisinopril, enalaprilat and captopril to angiotensin-converting enzyme. Biophys. Chem., 2004, 111, 183-189.
82. Dive, V.; Cotton, J.; Yiotakis, A.; Michaud, A.; Vassiliou, S.; Jiracek, J.; Vazeux, G.; Chauvet, M.T.; Cuniasse, P.; Corvol, P. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Natl. Acad. Sci. USA, 1999, 96, 4330-4335.
83. Junot, C.; Gonzales, M.F.; Ezan, E.; Cotton, J.; Vazeux, G.; Michaud, A.; Azizi, M.; Vassiliou, S.; Yiotakis, A.; Corvol, P.; Dive, V. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J. Pharmacol. Exp. Ther., 2001, 297, 606-611.
84. van Esch, J.H.M.; Tom, B.; Dive, V.; Batenburg, W.W.; Georgiadis, D.; Yiotakis, A.; van Gool, J.M.G.; de Bruijn, R.J.A.; de Vries, R.; Danser, A.H.J. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension, 2005, 45, 120-125.
85. Krege, J.H.; John, S.W.; Langenbach, L.L.; Hodgin, J.B.; Hagaman, J.R.; Bachman, E.S.; Jennette, J.C.; O'Brien, D.A.; Smithies, O. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature, 1995, 375, 146-148.
86. Esther, C.R.; Jr.; Howard, T.E.; Marino, E.M.; Goddard, J.M.; Capecchi, M.R.; Bernstein, K.E. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab. Invest., 1996, 74, 953-965.
87. Tian, B.; Meng, Q.C.; Chen, Y.F.; Krege, J.H.; Smithies, O.; Oparil, S. Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function. Hypertension, 1997, 30, 128-133.
88. Cole, J.; Ertoy, D.; Bernstein, K.E. Insights derived from ACE knockout mice. J. Renin Angiotensin Aldosterone Syst., 2000, 1, 137-141.
89. Fuchs, S.; Xiao, H.D.; Cole, J.M.; Adams, J.W.; Frenzel, K.; Michaud, A.; Zhao, H.; Keshelava, G.; Capecchi, M.R.; Corvol, P.; Bernstein, K.E. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J. Biol. Chem., 2004, 279, 15946-15953.
90. Rousseau, A.; Michaud, A.; Chauvet, M.T.; Lenfant, M.; Corvol, P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem., 1995, 270, 3656-3661.
91. Fuchs, S.; Xiao, H.D.; Hubert, C.; Michaud, A.; Campbell, D.J.; Adams, J.W.; Capecchi, M.R.; Corvol, P.; Bernstein, K.E. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension, 2007, 51, 267-274.
92. Bonnet, D.; Lemoine, F.M.; Khoury, E.; Pradelles, P.; Najman, A.; Guigon, M. Reversible inhibitory effects and absence of toxicity of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in human long-term bone marrow culture. Exp. Hematol., 1992, 20, 1165-1169.
93. Rasoul, S.; Carretero, O.A.; Peng, H.; Cavasin, M.A.; Zhuo, J.; Sanchez-Mendoza, A.; Brigstock, D.R.; Rhaleb, N.E. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J. Hypertens., 2004, 22, 593-603.
94. Sharma, U.; Rhaleb, N.E.; Pokharel, S.; Harding, P.; Rasoul, S.; Peng, H.; Carretero, O.A. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am. J. Physiol. Heart Circ. Physiol., 2008, 294, H1226-H1232.
95. Peng, H.; Carretero, O.A.; Liao, T.D.; Peterson, E.L.; Rhaleb, N.E. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. Hypertension, 2007, 49, 695-703.
96. Tang, S.C.; Leung, J.C.; Chan, L.Y.; Eddy, A.A.; Lai, K.N. Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy. Kidney Int., 2008, 73, 288-299.
97. Shibuya, K.; Kanasaki, K.; Isono, M.; Sato, H.; Omata, M.; Sugimoto, T.; Araki, S.; Isshiki, K.; Kashiwagi, A.; Haneda, M.; Koya, D. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes, 2005, 54, 838-845.
98. Watermeyer, J.M.; Kröger, W.L.; O'Neill, H.G.; Sewell, B.T.; Sturrock, E.D. Probing the basis of domain-dependent inhibition using novel ketone inhibitors of angiotensin-converting enzyme. Biochemistry, 2008, 47, 5942-5950.
99. Redelinghuys, P.; Nchinda, A.T.; Chibale, K.; Sturrock, E.D. Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling. Biol. Chem., 2006, 387, 461-466.
100. Nchinda, A.T.; Chibale, K.; Redelinghuys, P.; Sturrock, E.D. Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme. Bioorg. Med. Chem. Lett., 2006, 16, 4616-4619.
101. Georgiadis, D.; Cuniasse, P.; Cotton, J.; Yiotakis, A.; Dive, V. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. Biochemistry, 2004, 43, 8048-8054.
102. Perich, R.B.; Jackson, B.; Johnston, C.I. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. Eur. J. Pharmacol., 1994, 266, 201-211.
103. Fyhrquist, F.; Saijonmaa, O. Renin-angiotensin system revisited. J. Intern. Med., 2008, 264, 224-236.
104. Semple, P.F. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J. Hypertens. Suppl., 1995, 13, S17-S21.
105. Lalloo, U.G.; Barnes, P.J. & Chung, K.F. Pathophysiology and clinical presentations of cough. J. Allergy Clin. Immunol., 1996, 98, S91-S96; discussion S96-S97.
106. Byrd, J.B.; Adam, A.; and Brown, N.J. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol. Allergy Clin. Am., 2006, 26, 725-737.